Angiopoietin/Tie2 pathway mediates type 2 diabetes induced vascular damage after cerebral stroke

Neurobiology of Disease

Volumn 43, Issue 1, 2011, Pages 285-292

  Cui, Xu ^a   Chopp, Michael ^a,b   Zacharek, Alex ^a   Ye, Xinchun ^a   Roberts, Cynthia ^a   Chen, Jieli ^a  

^a HENRY FORD HOSPITAL   (United States)

^b OAKLAND UNIVERSITY   (United States)

Author keywords

Angiopoietin; Diabetes; Mice; Stroke; Vascular damage

Indexed keywords

ANGIOPOIETIN; ANGIOPOIETIN 1; ANGIOPOIETIN 2; ANGIOPOIETIN RECEPTOR; CELL PROTEIN; GLUCOSE; TIGHT JUNCTION PROTEIN; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERIOLAR DENSITY; ARTERIOLAR WALL MURAL CELL NUMBER; ARTERY CELL MIGRATION; ARTICLE; BLOOD BRAIN BARRIER; BLOOD VESSEL DIAMETER; BLOOD VESSEL WALL; BRAIN BLOOD VESSEL; BRAIN BLOOD VESSEL LEAKAGE; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CELL COUNT; CELL CULTURE; CELL MIGRATION; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DENSITY; COMMON CAROTID ARTERY; CONTROLLED STUDY; DISEASE MODEL; ENDOTHELIUM CELL; GENE EXPRESSION; GLUCOSE BLOOD LEVEL; IN VITRO STUDY; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; MORTALITY; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; VASCULAR LESION; VASCULARIZATION;

ANGIOPOIETIN-1; ANGIOPOIETIN-2; ANIMALS; CELLS, CULTURED; CEREBRAL ARTERIES; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DISEASE MODELS, ANIMAL; DOWN-REGULATION; INFARCTION, MIDDLE CEREBRAL ARTERY; MALE; MICE; MICE, TRANSGENIC; RECEPTOR PROTEIN-TYROSINE KINASES; UP-REGULATION;

EID: 79955951759     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2011.04.005     Document Type: Article

References (34)

1. Badillo A.T., et al. Treatment of diabetic wounds with fetal murine mesenchymal stromal cells enhances wound closure. Cell Tissue Res. 2007, 329:301-311.
2. Basu A.K., et al. Risk factor analysis in ischaemic stroke: a hospital-based study. J. Indian Med. Assoc. 2005, 103(586):588.
3. Bullock J.J., et al. Hyperglycemia-enhanced ischemic brain damage in mutant manganese SOD mice is associated with suppression of HIF-1alpha. Neurosci. Lett. 2009, 456:89-92.
4. Capes S.E., et al. Stress hyperglycemia and prognosis of stroke in nondiabetic and diabetic patients: a systematic overview. Stroke 2001, 32:2426-2432.
5. Chen J.X., Stinnett A. Ang-1 gene therapy inhibits hypoxia-inducible factor-1alpha (HIF-1alpha)-prolyl-4-hydroxylase-2, stabilizes HIF-1alpha expression, and normalizes immature vasculature in db/db mice. Diabetes 2008, 57:3335-3343.
6. Chen J.X., Stinnett A. Disruption of Ang-1/Tie-2 signaling contributes to the impaired myocardial vascular maturation and angiogenesis in type II diabetic mice. Arterioscler. Thromb. Vasc. Biol. 2008, 28:1606-1613.
7. Chen J., et al. White matter damage and the effect of matrix metalloproteinases in type 2 diabetic mice after stroke. Stroke 2011, 42:445-452.
8. Cui X., et al. Nitric oxide donor up-regulation of SDF1/CXCR4 and Ang1/Tie2 promotes neuroblast cell migration after stroke. J. Neurosci. Res. 2009, 87:86-95.
9. Ebrahimian T.G., et al. Dual effect of angiotensin-converting enzyme inhibition on angiogenesis in type 1 diabetic mice. Arterioscler. Thromb. Vasc. Biol. 2005, 25:65-70.
10. Elewa H.F., et al. Early atorvastatin reduces hemorrhage after acute cerebral ischemia in diabetic rats. J. Pharmacol. Exp. Ther. 2009, 330:532-540.
11. Ennis S.R., Keep R.F. Effect of sustained-mild and transient-severe hyperglycemia on ischemia-induced blood-brain barrier opening. J. Cereb. Blood Flow Metab. 2007, 27:1573-1582.
12. Ergul A., et al. Increased hemorrhagic transformation and altered infarct size and localization after experimental stroke in a rat model type 2 diabetes. BMC Neurol. 2007, 7:33.
13. Feng Y., et al. Impaired pericyte recruitment and abnormal retinal angiogenesis as a result of angiopoietin-2 overexpression. Thromb. Haemost. 2007, 97:99-108.
14. Ho T.K., et al. Increased angiogenic response but deficient arteriolization and abnormal microvessel ultrastructure in critical leg ischaemia. Br. J. Surg. 2006, 93:1368-1376.
15. Iurlaro M., et al. Rat aorta-derived mural precursor cells express the Tie2 receptor and respond directly to stimulation by angiopoietins. J. Cell Sci. 2003, 116:3635-3643.
16. Li W., et al. Adaptive cerebral neovascularization in a model of type 2 diabetes: relevance to focal cerebral ischemia. Diabetes 2010, 59:228-235.
17. Liu X.S., et al. Comparison of in vivo and in vitro gene expression profiles in subventricular zone neural progenitor cells from the adult mouse after middle cerebral artery occlusion. Neuroscience 2007, 146:1053-1061.
18. Liu L., et al. Age-dependent impairment of HIF-1alpha expression in diabetic mice: correction with electroporation-facilitated gene therapy increases wound healing, angiogenesis, and circulating angiogenic cells. J. Cell. Physiol. 2008, 217:319-327.
19. Metheny-Barlow L.J., et al. Direct chemotactic action of angiopoietin-1 on mesenchymal cells in the presence of VEGF. Microvasc. Res. 2004, 68:221-230.
20. Mooradian A.D., et al. Statins ameliorate endothelial barrier permeability changes in the cerebral tissue of streptozotocin-induced diabetic rats. Diabetes 2005, 54:2977-2982.
21. Nag S., et al. Increased angiopoietin2 expression is associated with endothelial apoptosis and blood-brain barrier breakdown. Lab. Invest. 2005, 85:1189-1198.
22. Pfister F., et al. Pericyte migration: a novel mechanism of pericyte loss in experimental diabetic retinopathy. Diabetes 2008, 57:2495-2502.
23. Pfister F., et al. Retinal overexpression of angiopoietin-2 mimics diabetic retinopathy and enhances vascular damages in hyperglycemia. Acta Diabetol. 2010, 47:59-64.
24. Rangasamy S., et al. A potential role for angiopoietin 2 in the regulation of the blood-retinal barrier in diabetic retinopathy. Invest. Ophthalmol. Vis. Sci. 2011, [Epub ahead of print].
25. Singh H., et al. High glucose and elevated fatty acids suppress signaling by the endothelium protective ligand angiopoietin-1. Microvasc. Res. 2010, 79:121-127.
26. Suri C., et al. Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell 1996, 87:1171-1180.
27. Suri C., et al. Increased vascularization in mice overexpressing angiopoietin-1. Science 1998, 282:468-471.
28. Van Slyke P., et al. Acceleration of diabetic wound healing by an angiopoietin peptide mimetic. Tissue Eng. A 2009, 15:1269-1280.
29. vom Hagen F., et al. Early loss of arteriolar smooth muscle cells: more than just a pericyte loss in diabetic retinopathy. Exp. Clin. Endocrinol. Diabetes 2005, 113:573-576.
30. Waltenberger J. Impaired collateral vessel development in diabetes: potential cellular mechanisms and therapeutic implications. Cardiovasc. Res. 2001, 49:554-560.
31. Watanabe D., et al. Vitreous levels of angiopoietin 2 and vascular endothelial growth factor in patients with proliferative diabetic retinopathy. Am. J. Ophthalmol. 2005, 139:476-481.
32. Weihrauch D., et al. Chronic hyperglycemia attenuates coronary collateral development and impairs proliferative properties of myocardial interstitial fluid by production of angiostatin. Circulation 2004, 109:2343-2348.
33. Zhang Z.G., Chopp M. Neurorestorative therapies for stroke: underlying mechanisms and translation to the clinic. Lancet Neurol. 2009, 8:491-500.
34. Zhang Z.G., et al. Angiopoietin-1 reduces cerebral blood vessel leakage and ischemic lesion volume after focal cerebral embolic ischemia in mice. Neuroscience 2002, 113:683-687.